Grn163l
- Generic Name
- Grn163l
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the its potential utility in the treatment of patient...
- Indication
Investigated for use/treatment in leukemia (lymphoid) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00732056
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT00124189
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.